UBS Group
COEPW

UBS Group’s Coeptis Therapeutics Warrants COEPW Stock Holding History

UBS Group’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279 Buy
23,227
+19,600
+540% +$235 ﹤0.01% 9983
2025
Q4 		$40 Buy
+3,627
New +$63 ﹤0.01% 10295
2025
Q1 		– Sell
-678
Closed -$15 – 10280
2024
Q4 		$15 Buy
678
+634
+1,441% +$15 ﹤0.01% 9789
2024
Q3 		$1 Sell
44
-4,943
-99% -$99 ﹤0.01% 9422
2024
Q2 		$75 Buy
4,987
+4,900
+5,632% +$123 ﹤0.01% 9197
2024
Q1 		$2 Buy
+87
New +$4 ﹤0.01% 9181
2023
Q4 		– Sell
-100
Closed -$2 – 9372
2023
Q3 		$2 Buy
+100
New +$4 ﹤0.01% 9345
2022
Q4 		– Sell
-13,105
Closed – – 10770
2022
Q3 		$0 Buy
13,105
+2,800
+27% +$134 ﹤0.01% 10407
2022
Q2 		$0 Buy
+10,305
New +$774 ﹤0.01% 10386
2021
Q4 		– Sell
-596
Closed – – 10302
2021
Q3 		$0 Sell
596
-6,883
-92% -$2.62K ﹤0.01% 9601
2021
Q2 		$4K Buy
7,479
+559
+8% +$284 ﹤0.01% 8656
2021
Q1 		$3K Buy
6,920
+6,588
+1,984% +$6.18K ﹤0.01% 8507
2020
Q4 		$0 Buy
+332
New +$306 ﹤0.01% 8425

Other funds holding COEPW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's COEPW Position: Q1 2026 in Review

UBS Group increased its Coeptis Therapeutics Warrants (COEPW) stake by 540% in Q1 2026, buying an estimated $235 and bringing the position to 23,227 shares worth $279. The position accounts for ﹤0.01% of the portfolio, ranked #9983.

UBS Group first reported a position in COEPW in Q4 2020 and has held it in 13 quarters since. The position peaked at $4K in Q2 2021. 10 funds tracked by Wall St. Rank hold COEPW as of Q1 2026.

  • UBS Group held 23,227 shares of Coeptis Therapeutics Warrants worth $279 as of Q1 2026.
  • UBS Group bought 19,600 Coeptis Therapeutics Warrants shares in Q1 2026, an estimated $235.
  • Coeptis Therapeutics Warrants made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9983 holding.
  • UBS Group first reported a position in Coeptis Therapeutics Warrants in Q4 2020 and has held it in 13 quarters since.
  • UBS Group's Coeptis Therapeutics Warrants position peaked at $4K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.